Chemo-enzymatic cascade processes are invaluable due to their ability to rapidly construct high-value products from available feedstock chemicals in a one-pot relay manner. COA of Formula: C8H4Cl2N2, In a article, mentioned the application of 2213-63-0, Name is 2,3-Dichloroquinoxaline, molecular formula is C8H4Cl2N2
Bromodomain and extra-terminal (BET) proteins, a class of epigenetic reader domains has emerged as a promising new target class for small molecule drug discovery for the treatment of cancer, inflammatory, and autoimmune diseases. Starting from in silico screening campaign, herein we report the discovery of novel BET inhibitors based on [1,2,4]triazolo[4,3-a]quinoxaline scaffold and their biological evaluation. The hit compound was optimized using the medicinal chemistry approach to the lead compound with excellent inhibitory activities against BRD4 in the binding assay. The substantial antiproliferative activities in human cancer cell lines, promising drug-like properties, and the selectivity for the BET family make the lead compound (13) as a novel BRD4 inhibitor motif for anti-cancer drug discovery.
If you are interested in 2213-63-0, you can contact me at any time and look forward to more communication. COA of Formula: C8H4Cl2N2
Reference：
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1247 | ChemSpider